A double-purified botulinum toxin from Germany that temporarily relaxes targeted facial muscles to soften dynamic wrinkles, without unnecessary accessory proteins.
XEOMIN (IncobotulinumtoxinA) is a botulinum toxin type A injectable neuromodulator manufactured by Merz Aesthetics in Germany. It temporarily relaxes targeted facial muscles, softening dynamic wrinkles such as forehead lines, frown lines, and crow's feet. Unlike dermal fillers or skin boosters, XEOMIN doesn't add volume or improve skin quality directly, it works by temporarily blocking nerve signals to muscles, reducing contraction and smoothing expression lines. It's approved in more than 80 countries and has been used in over 20 million aesthetic treatments worldwide.
XEOMIN is the first and only double-purified botulinum toxin type A that removes the complexing (accessory) proteins, leaving only the active neurotoxin, a process Merz markets as XTRACT TECHNOLOGY™. Each vial contains the purified toxin along with human albumin and sucrose, with no unnecessary accessory proteins, intended to reduce unneeded protein exposure while maintaining clinical efficacy.
Treatment is typically repeated every 3 to 4 months, with dosing individualized to muscle strength, facial anatomy, treatment goals, and previous toxin response. Many patients receive 3 to 4 sessions per year to maintain results. Onset begins around 3 to 4 days, full effect develops over 10 to 14 days, and peak effect is usually seen at 2 to 4 weeks.
Because these risks exist with any injectable or energy-based treatment, procedures should only be performed by trained, licensed medical professionals with expertise in facial anatomy.
XEOMIN is FDA-approved in the United States for glabellar lines, forehead lines, and crow's feet, and holds approvals in many countries worldwide for both cosmetic and therapeutic indications.
XEOMIN is widely regarded as one of the leading premium botulinum toxin brands, alongside BOTOX® and Dysport®. Its defining characteristic is a high-purity formulation without complexing proteins, achieved through Merz's double-purification process, which has made it particularly attractive to patients anticipating long-term, repeated treatment. Studies generally show comparable efficacy, onset, and duration among approved neuromodulators at equivalent doses, with outcomes depending more on injector expertise and individual response than on brand alone.
